SPOTLIGHT: Avexa gains rights to HIV drug

Shire has licensed the North American rights to the HIV compound SPD754 to Australia's Avexa in exchange for an up front payment of $10 million and sales and development milestones. Shire gets eight million shares of Avexa in the deal, boosting its stake in the company to eight percent. Release | Report